CBIO
CRESCENT BIOPHARMA, INC.
Key Financials
Revenue
$10.8M
↑ Infinity%
Net Income
$-153942000
↓ 306.4%
Operating Income
$-152632000
↓ 281.2%
EPS (Diluted)
$-0.59
↓ 1.7%
Total Assets
$240.3M
↑ 2066.5%
Total Liabilities
$37.3M
↑ 545.2%
Shareholders' Equity
$203.0M
↑ 3720.6%
Cash & Equivalents
$213.2M
↑ 1888.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| EFFECT | 7/31/2026 | View on SEC |
| POS AM | 7/30/2026 | View on SEC |
| 424B3 | 7/30/2026 | View on SEC |
| 10-Q | 7/30/2026 | View on SEC |
| 8-K | 7/30/2026 | View on SEC |
| SCHEDULE 13D/A | 7/20/2026 | View on SEC |
| 4 | 7/20/2026 | View on SEC |
| 8-K | 7/15/2026 | View on SEC |
| 424B5 | 7/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CBIO |
| Company Name | CRESCENT BIOPHARMA, INC. |
| CIK | 1253689 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | E9 |
| Phone | 617-430-5595 |